Comprehensive M&A data with integrated detailed company information
ACS picks up Amplify’s units
Posted on Tuesday, 30 June 2020 13:30
Accel Clinical Services (ACS) has acquired the assets of US-based clinical trial platform Amplify Clinical.
Financial terms were not disclosed.
ASC will pick up Amplify’s Meridien Research, its NeuroStudies destination unit and the group’s site business development division, InSearch Site Network.
The combined enterprise will create a Southeastern US clinical research company comprising over 100 employees and multi-phase and multi-therapeutic capabilities, which will help serve sponsors and contract research organisations (CROs).
Following the transaction, the enlarged group will operate from ASC’s newly established corporate office in Florida.
Amplify houses a platform of medical research sites and related services companies, which support and carry out critical research for patients across multiple therapeutic areas.
Its InSearch division works with sponsors and CROs to ensure successful clinical trials and focuses on the oncology, psychiatry and gastroenterology segments, among others.
NeuroStudies also carries out studies for Alzheimer’s disease, Parkinson’s and other central nervous system conditions.
ASC plans to use the acquisition to expand its research capabilities and provide customers with as many treatments as possible.
Matt Maxwell, chief executive of the buyer, said: “All providers and patients deserve access to clinical trials. It is our duty to help patients in need get access to novel treatments, especially when no effective options are approved for general use.”
ASC operates a range of clinical research sites across the US, including in Florida, Georgia and Alabama.
The group’s centres span multiple therapeutic areas, namely dermatology, gastroenterology, gynaecology and cardiology.
According to Zephyr, the M&A database published by Bureau van Dijk, shows there have been 2,633 deals targeting scientific research and development companies announced globally in 2020 to date.
Gilead Sciences agreed to purchase US-based Forty Seven for USD 4.90 billion in the largest of these.
Corvidia Therapeutics, Aprogen and Moderna, among other companies, were also targeted in this sector.
© Zephus Ltd